Saturday 17 October 2026
Export KYNB’s income statement to Excel — free account
Kyntra Bio Inc
KYNB Healthcare Biotechnology
In the quarter to June 2026, revenue fell 209.4%, EPS grew 257.5% and free cash flow fell 131.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.85
0.51
−9.51%
Follow KYNB
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
5 | 2 | 2 | 1 | 2 | 3 | 3 | 4 | 3 | 5 |
Altman Z-Score |
(20.33) | (14.08) | (8.08) | (3.07) | (1.39) | 3.85 | 6.44 | 6.23 | 5.53 | 1.89 |
P/S ratio |
5.51 | 1.79 | 1.73 | 10.61 | 5.53 | 18.90 | 14.48 | 18.27 | 28.25 | 7.30 |
Altman Z″-Score (non-manufacturers) |
(45.38) | (32.01) | (17.85) | (9.28) | (5.28) | 0.50 | 2.65 | 2.74 | 3.31 | (0.54) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.94 | 0.00 | 0.00 | 0.00 | 228.22 |
Beneish M-Score |
(4.57) | (3.55) | (3.39) | (3.87) | (1.66) | (3.66) | (2.67) | 2.29 | (3.19) | (3.60) |
P/Operating CF |
(1.94) | (1.74) | (4.41) | (28.42) | (23.69) | (461.08) | (82.48) | (222.75) | (3,120.12) | (72.07) |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 5.68 | 7.55 | 6.94 | 7.36 | 6.76 | 7.63 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 5.68 | 7.55 | 6.94 | 7.36 | 6.76 | 7.63 |
EV/Sales |
14.55 | 2.95 | (0.83) | 8.37 | 4.31 | 15.23 | 12.60 | 15.81 | 23.38 | 6.44 |
EV/EBITDA |
0.00 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(19.62) | (0.63) | 0.12 | (8.07) | (12.33) | 32.90 | (41.08) | (44.21) | (46.04) | 166.10 |
EV/FCF |
(19.47) | (0.64) | 0.12 | (6.38) | (9.02) | 34.60 | (38.28) | (40.08) | (40.83) | 201.61 |
Quick Ratio |
3.05 | 0.38 | 0.96 | 1.60 | 1.87 | 4.46 | 5.47 | 7.69 | 8.66 | 4.05 |
Current Ratio |
3.39 | 1.47 | 1.52 | 1.80 | 2.10 | 4.63 | 6.84 | 7.75 | 8.71 | 4.09 |
Net Debt/EBITDA |
1.97 | (0.15) | 0.41 | 1.13 | 1.10 | 3.90 | 6.94 | 6.40 | 5.83 | 3.78 |
Debt/Assets |
0.00% | 34.07% | 16.98% | 15.84% | 13.75% | 3.07% | 4.39% | 12.26% | 10.88% | 20.73% |
Debt/Equity |
0.00 | (0.36) | (0.39) | (65.30) | 0.46 | 0.06 | 0.07 | 0.20 | 0.18 | 0.56 |
Asset Turnover |
0.04 | 0.09 | 0.09 | 0.20 | 0.29 | 0.21 | 0.30 | 0.24 | 0.19 | 0.39 |
Operating CF/Net income |
(0.03) | 2.90 | 1.11 | 0.50 | 0.28 | (0.43) | 1.02 | 0.88 | 0.55 | (0.12) |
Capex/Depreciation |
(0.06) | 0.77 | (0.52) | (3.17) | (1.75) | (0.18) | (0.32) | (1.20) | (1.07) | (0.14) |
Interest Coverage |
(5.24) | (18.24) | (39.87) | (209.05) | (268.40) | (79.88) | (31.05) | (7.89) | (12.08) | (4.67) |
| (165.18%) | 24.48% | 307.01% | (258.01%) | (86.50%) | (38.76%) | (14.47%) | (16.06%) | (33.44%) | (31.22%) | |
| 109.81% | (14.91%) | (55.00%) | (42.44%) | (36.24%) | (22.48%) | (8.86%) | (9.71%) | (17.67%) | (12.35%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (142.19%) | (360.67%) | 0.00% | (162.20%) |
Return on Tangible Assets |
262.71% | (75.28%) | (239.50%) | (122.42%) | (104.76%) | (30.26%) | (11.98%) | (11.87%) | (15.25%) | (17.86%) |
Average Days of Receivables |
12.24 | 5.93 | 39.94 | 42.27 | 26.99 | 86.70 | 40.48 | 109.15 | 23.55 | 20.82 |
Research and Development Expense of Revenue |
365.17% | 323.05% | 569.35% | 210.89% | 164.48% | 143.45% | 81.56% | 110.74% | 150.02% | 102.19% |
Selling, General and Administrative Expense of Revenue |
430.26% | 166.54% | 184.78% | 88.60% | 52.66% | 60.35% | 52.80% | 29.96% | 39.51% | 25.12% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
102.11% | 85.13% | 108.47% | 46.61% | 30.24% | 41.24% | 25.83% | 24.48% | 28.66% | 17.54% |
Graham Net Nets |
(1.06) | (4.21) | (3.41) | (0.08) | (0.05) | 0.11 | 0.10 | 0.09 | 0.11 | (0.02) |
Graham Number |
0.00 | 117.64 | 278.89 | 26.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
517.88% | (90.57%) | (352.50%) | (19.69%) | (22.27%) | (5.72%) | (2.05%) | (2.23%) | (3.39%) | (4.60%) |
Free Cash Flow Yield |
(13.56%) | (258.77%) | (393.35%) | (12.37%) | (8.63%) | 2.33% | (2.27%) | (2.16%) | (2.03%) | 0.44% |
Revenue per Share |
1.59 | 7.40 | 12.03 | 37.60 | 63.70 | 49.06 | 74.04 | 63.33 | 44.87 | 72.99 |
Operating CF per Share |
(1.18) | (34.48) | (80.94) | (38.99) | (22.26) | 22.70 | (22.71) | (22.65) | (22.78) | 2.83 |
Capex per Share |
(0.01) | 0.19 | (0.65) | (10.35) | (8.17) | (1.11) | (1.66) | (2.33) | (2.91) | (0.50) |
Free Cash Flow per Share |
(1.19) | (34.29) | (81.59) | (49.33) | (30.43) | 21.59 | (24.37) | (24.98) | (25.69) | 2.33 |
Cash per Share |
22.01 | 12.61 | 52.27 | 112.74 | 109.69 | 191.01 | 154.03 | 184.80 | 252.00 | 100.88 |
Shareholders Equity per Share |
(4.21) | (51.25) | (47.19) | (0.40) | 62.02 | 122.82 | 154.50 | 157.17 | 187.61 | 69.77 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(4.21) | (51.25) | (47.19) | (0.40) | 62.02 | 122.82 | 154.50 | 157.17 | 187.61 | 69.77 |
Free Cash Flow |
(4.81) | (137.22) | (317.54) | (184.67) | (112.42) | 77.61 | (84.46) | (83.98) | (75.01) | 5.86 |
Working Capital |
69.83 | 63.20 | 113.89 | 219.26 | 248.56 | 591.92 | 599.75 | 600.98 | 663.01 | 201.39 |
Capital Expenditures |
(0.04) | 0.78 | (2.52) | (38.73) | (30.19) | (3.99) | (5.75) | (7.84) | (8.49) | (1.25) |
Net Current Asset Value |
(37.53) | (223.13) | (275.65) | (118.74) | (70.65) | 369.72 | 380.50 | 337.89 | 398.06 | (27.93) |
EV/EBIT |
0.00 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | (0.03) | 0.05 | 0.28 | 0.13 | 0.02 | 0.02 | 0.04 | 0.06 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 1.02 | 0.59 | 0.61 | 0.66 | 0.42 | 0.05 | 0.06 | 0.07 |
Cash ROIC |
(6.69%) | 168.28% | (346.26%) | (35.71%) | (15.18%) | 6.73% | (7.63%) | (6.68%) | (5.43%) | 1.11% |
Accounts Receivable Turnover |
18.48 | 10.58 | 4.37 | 8.35 | 7.94 | 5.01 | 5.57 | 5.90 | 13.86 | 14.17 |
Accounts Payable Turnover |
0.13 | 1.49 | 0.17 | 0.71 | 0.51 | 0.57 | 0.15 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.16 | 1.53 | 0.14 | 0.57 | 0.54 | 0.76 | 0.10 | — | — | — |
Average Days of Payables |
2,458.50 | 118.78 | 1,453.55 | 553.58 | 740.07 | 1,020.18 | 1,937.33 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
2,457.19 | 74.00 | 1,582.07 | 727.77 | 879.53 | 680.29 | 2,191.59 | — | — | — |
Average Receivables |
0.35 | 2.80 | 10.71 | 16.85 | 29.64 | 35.17 | 46.07 | 36.07 | 9.45 | 12.93 |
Average Payables |
4.40 | 10.42 | 23.27 | 28.43 | 25.44 | 15.44 | 7.61 | 7.32 | 5.87 | 6.37 |
Average Inventory |
3.45 | 10.16 | 28.80 | 35.73 | 23.77 | 11.71 | 11.71 | — | — | — |
Average Assets |
167.06 | 319.03 | 516.81 | 691.95 | 800.33 | 842.12 | 869.00 | 889.62 | 684.10 | 470.06 |
Average Common Equity |
(111.06) | (194.40) | (92.58) | 113.82 | 335.28 | 488.43 | 531.94 | 538.10 | 361.42 | 185.97 |
Columns are period end dates